rosiglitazone has been researched along with Cirrhosis, Liver in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, Z; Deng, L; Geng, X; Hu, L; Jiao, S; Li, Z; Ren, Q; Wang, B; Yang, Y; Zhang, L; Zhou, Z | 1 |
| Ahn, KJ; Bang, K; Chung, HY; Hwang, YC; Jeong, IK; Jun, JE; Yoo, J; Yum, YJ | 1 |
| Chen, Y; Duan, Y; Han, J; Li, Q; Li, X; Wei, Z; Yang, X; Zeng, P; Zhang, S; Zhang, W; Zhang, Y; Zhao, D | 1 |
| Atkin, SL; De Vincentis, A; Jamialahmadi, T; Mahjoubin-Tehran, M; Mantzoros, CS; Mikhailidis, DP; Sahebkar, A | 1 |
| Hsu, WH; Hsu, YW; Lee, BH; Pan, TM | 1 |
| Kumar, V; Mahato, RI; Mundra, V | 1 |
| Fu, N; Nan, YM; Yu, J | 1 |
| Fu, N; Liang, BL; Nan, YM; Wang, RQ; Wu, WJ; Yu, J; Zhao, JM; Zhao, SX | 1 |
| Chalasani, N; Vuppalanchi, R | 1 |
| Feng, YS; Ma, H; Yue, LP | 1 |
| Bernhardt, C; Bruckert, E; Charlotte, F; Giral, P; Halbron, M; Hartmann-Heurtier, A; Lenaour, G; Poynard, T; Ratziu, V | 1 |
| Ackerman, Z; Grozovski, M; Oron-Herman, M; Pappo, O; Peleg, E; Safadi, R; Schmilovitz-Weiss, H | 1 |
| Han, F; Kong, LB; Nan, YM; Wang, RQ; Wu, WJ; Yu, J; Zhao, SX | 1 |
| Baumann, U; Bhathal, PS; Brown, RM; Brunt, EM; Clouston, AD; Couper, RT; Dixon, JB; Ee, LC; Jonsson, JR; Manton, ND; Moschen, AR; Neuschwander-Tetri, BA; O'Brien, PE; Powell, EE; Richardson, MM; Skoien, R; Tilg, H; Weltman, M | 1 |
| Li, MG; Lü, XH; Wu, XY; Yu, JP; Zhou, XH | 1 |
| Chen, H; He, YW; Liu, WQ; Zhang, JH | 1 |
| Casini, A; Ceni, E; Crabb, DW; Galli, A; Mello, T; Ridolfi, F; Salzano, R; Surrenti, C; Svegliati-Baroni, G; Trozzi, L | 1 |
2 review(s) available for rosiglitazone and Cirrhosis, Liver
| Article | Year |
|---|---|
Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
Topics: Biopsy; Disease Progression; Humans; Liver; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Severity of Illness Index; Treatment Outcome; Ursodeoxycholic Acid; Vitamin E | 2021 |
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
Topics: Bariatric Surgery; Biomarkers; Biopsy; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Exercise; Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Cirrhosis; Liver Diseases; Metabolic Syndrome; Metformin; Obesity; Oxidative Stress; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Weight Loss | 2009 |
1 trial(s) available for rosiglitazone and Cirrhosis, Liver
| Article | Year |
|---|---|
Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial.
Topics: Double-Blind Method; Fatty Liver; Female; Humans; Hypoglycemic Agents; Liver Cirrhosis; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Time Factors | 2010 |
14 other study(ies) available for rosiglitazone and Cirrhosis, Liver
| Article | Year |
|---|---|
Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents.
Topics: Animals; Chenodeoxycholic Acid; Drug Discovery; Gene Expression Regulation; Humans; Hypoglycemic Agents; Liver Cirrhosis; Male; Mice, Inbred C57BL; Mice, Inbred ICR; Models, Molecular; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Peroxisome Proliferator-Activated Receptors; Protein Binding; Receptors, G-Protein-Coupled; Structure-Activity Relationship | 2022 |
Peroxisome proliferator-activated receptor γ activation ameliorates liver fibrosis-differential action of transcription factor EB and autophagy on hepatocytes and stellate cells.
Topics: Animals; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Hepatic Stellate Cells; Hepatocytes; Humans; Liver Cirrhosis; Mice; PPAR gamma; Rosiglitazone | 2023 |
Rosiglitazone ameliorates bile duct ligation-induced liver fibrosis by down-regulating NF-κB-TNF-α signaling pathway in a PPARγ-dependent manner.
Topics: Animals; Apoptosis; Bile Ducts; Collagen Type I; Collagen Type I, alpha 1 Chain; Hypoglycemic Agents; Ligation; Liver; Liver Cirrhosis; Mice, Knockout; NF-kappa B; PPAR gamma; Rosiglitazone; Signal Transduction; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha | 2019 |
Peroxisome proliferator-activated receptor-γ activators monascin and rosiglitazone attenuate carboxymethyllysine-induced fibrosis in hepatic stellate cells through regulating the oxidative stress pathway but independent of the receptor for advanced glycat
Topics: Animals; Anti-Inflammatory Agents; beta-Glucans; Cells, Cultured; Hepatic Stellate Cells; Heterocyclic Compounds, 3-Ring; Liver Cirrhosis; Lysine; Male; Mice; Oxidative Stress; PPAR gamma; Receptor for Advanced Glycation End Products; Receptors, Immunologic; RNA, Small Interfering; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transfection | 2013 |
Nanomedicines of Hedgehog inhibitor and PPAR-γ agonist for treating liver fibrosis.
Topics: Anilides; Animals; Base Sequence; Cytokines; DNA Primers; Enzyme-Linked Immunosorbent Assay; Fluorescent Antibody Technique; Hedgehog Proteins; Inflammation Mediators; Liver Cirrhosis; Male; Nanomedicine; PPAR gamma; Proton Magnetic Resonance Spectroscopy; Pyridines; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones | 2014 |
[Effect of rosiglitazone in non-alcoholic steatohepatitis associated liver fibrosis].
Topics: Animals; Fatty Liver; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Rosiglitazone; Serum; Thiazolidinediones | 2008 |
Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Blotting, Western; Connective Tissue Growth Factor; Fatty Liver; Hepatic Stellate Cells; Hypoglycemic Agents; Immunoenzyme Techniques; Liver Cirrhosis; Liver Function Tests; Male; Mice; Mice, Inbred C57BL; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transforming Growth Factor beta1 | 2009 |
[Effects of rosiglitazone on expression of collagen I and tissue inhibitor of metalloproteinase 1 in rat hepatic stellate cells].
Topics: Animals; Cell Proliferation; Cell Survival; Cells, Cultured; Collagen; Extracellular Matrix; Hepatic Stellate Cells; Liver Cirrhosis; Male; PPAR gamma; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-1 | 2009 |
Hepatic effects of rosiglitazone in rats with the metabolic syndrome.
Topics: Adiponectin; alpha-Tocopherol; Animal Feed; Animals; Aryldialkylphosphatase; Blood Pressure; Fatty Liver; Fructose; Glutathione Reductase; Hypoglycemic Agents; Lipid Metabolism; Lipids; Liver; Liver Cirrhosis; Male; Malondialdehyde; Metabolic Syndrome; Phospholipids; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2010 |
Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice.
Topics: Adenoviridae; Anilides; Animals; beta-Galactosidase; Choline; Diet; Fatty Liver; Genetic Vectors; Inflammation; Liver Cirrhosis; Liver Cirrhosis, Experimental; Male; Methionine; Mice; Mice, Inbred C57BL; PPAR gamma; Random Allocation; Rosiglitazone; Thiazolidinediones; Transfection | 2011 |
Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways.
Topics: Adolescent; Adult; Age Factors; Australia; Bile Ducts, Intrahepatic; Biomarkers; Biopsy; Cell Proliferation; Child; Child, Preschool; Europe; Fatty Liver; Gastric Bypass; Humans; Immunohistochemistry; Keratin-7; Liver; Liver Cirrhosis; Missouri; Non-alcoholic Fatty Liver Disease; Risk Factors; Rosiglitazone; Stem Cells; Thiazolidinediones; Treatment Outcome | 2013 |
[Effect of rosiglitazone on metalloproteinase tissue inhibitor-1 in CCl4-induced liver fibrosis in rats].
Topics: Animals; Liver Cirrhosis; Male; Rats; Rats, Inbred Strains; Rosiglitazone; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-1 | 2006 |
Rosiglitazone prevents murine hepatic fibrosis induced by Schistosoma japonicum.
Topics: Actins; Animals; Anthelmintics; Collagen Type I; Collagen Type III; Disease Models, Animal; Hypoglycemic Agents; Interleukin-6; Liver; Liver Cirrhosis; Mice; NF-kappa B; PPAR gamma; Praziquantel; RNA, Messenger; Rosiglitazone; Schistosoma japonicum; Schistosomiasis japonica; Thiazolidinediones; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha | 2008 |
Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro.
Topics: Animals; Benzhydryl Compounds; Bile Ducts; Carbon Tetrachloride; Cell Division; Cells, Cultured; Collagen; Dimethylnitrosamine; DNA; Epoxy Compounds; Fibronectins; Hypoglycemic Agents; Ligation; Liver; Liver Cirrhosis; Male; Phenols; Pioglitazone; Promoter Regions, Genetic; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |